• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Centessa Pharmaceuticals plc

    6/24/26 6:32:05 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    Centessa Pharmaceuticals plc

    (Name of Issuer)


    Ordinary Shares, nominal value GBP 0.002 per share (the "Ordinary Shares")

    (Title of Class of Securities)




    152309100

    (CUSIP Number)
    Hannah E. Dunn
    Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100
    San Francisco, CA, 94111
    (415) 421-2132

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    06/16/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    FARALLON CAPITAL MANAGEMENT, L.L.C.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IA, OO



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Dapice Joshua J.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Dreyfuss, Philip D.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Dunn Hannah E.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Gehani, Varun N.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Giauque, Nicolas
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Husen, Avner A.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Kim, David T.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Linn, Michael G.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Luo Patrick (Cheng)
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CHINA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Roberts, Jr., Thomas G.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Saito Edric C.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Short Daniel S.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Spokes, Andrew J. M.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Warren, John R.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    CUSIP Number(s):
    152309100


    1 Name of reporting person

    Wehrly, Mark C.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,370,093.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,370,093.00
    11Aggregate amount beneficially owned by each reporting person

    9,370,093.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, nominal value GBP 0.002 per share (the "Ordinary Shares")
    (b)Name of Issuer:

    Centessa Pharmaceuticals plc
    (c)Address of Issuer's Principal Executive Offices:

    3rd Floor, 1 Ashley Road, Altrincham, Cheshire, UNITED KINGDOM , WA14 2DT.
    Item 2.Identity and Background
    (a)
    This Schedule 13D is filed by the entity and persons listed below, all of whom together are referred to herein as the "Reporting Persons." (i) Farallon Capital Management, L.L.C., a Delaware limited liability company (the "Investment Manager"), which is the investment manager of certain investment partnerships, including the Farallon Funds (as defined in Item 5), with respect to the Ordinary Shares, represented by ADSs (as defined below), held by the Farallon Funds; and (ii) The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Investment Manager, with respect to the Ordinary Shares, represented by ADSs, held by the Farallon Funds: Joshua J. Dapice ("Dapice"); Philip D. Dreyfuss ("Dreyfuss"); Hannah E. Dunn ("Dunn"); Varun N. Gehani ("Gehani"); Nicolas Giauque ("Giauque"); Avner A. Husen ("Husen"); David T. Kim ("Kim"); Michael G. Linn ("Linn"); Patrick (Cheng) Luo ("Luo"); Thomas G. Roberts, Jr. ("Roberts"); Edric C. Saito ("Saito"); Daniel S. Short ("Short"); Andrew J. M. Spokes ("Spokes"); John R. Warren ("Warren"); and Mark C. Wehrly ("Wehrly"). Dapice, Dreyfuss, Dunn, Gehani, Giauque, Husen, Kim, Linn, Luo, Roberts, Saito, Short, Spokes, Warren and Wehrly are together referred to herein as the "Farallon Individual Reporting Persons." There is no CUSIP assigned to the Ordinary Shares. The CUSIP number 152309100 has been assigned to the American Depositary Shares ("ADSs") of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol "CNTA." Each ADS represents one Ordinary Share.
    (b)
    The address of the principal business office of each of the Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.
    (c)
    The principal business of the Investment Manager is to act as the investment manager of various investment vehicles and partnerships, including the Farallon Funds. The principal occupation of Giauque is serving as Senior Managing Member of each of the Investment Manager and Farallon Partners, L.L.C., which is the general partner of certain investment partnerships advised by the Investment Manager, and as the Senior Manager of certain other general partners of investment partnerships advised by the Investment Manager. The principal occupation of each other Farallon Individual Reporting Person is serving as a Managing Member of each of the Investment Manager and Farallon Partners, L.L.C., and as a Manager of certain other general partners of investment partnerships advised by the Investment Manager.
    (d)
    None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    None of the Reporting Persons has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    The jurisdiction of organization of the Investment Manager is set forth above. Each of the Farallon Individual Reporting Persons, other than Giauque, Luo and Spokes, is a citizen of the United States. Giauque is a citizen of France. Luo is a citizen of China. Spokes is a citizen of the United Kingdom.
    Item 3.Source and Amount of Funds or Other Consideration
     
    The approximate net investment cost for the Ordinary Shares, represented by ADSs, held by the Farallon Funds is $325,995,909.
    Item 4.Purpose of Transaction
     
    The disclosure set forth in Items 5 and 6 below is hereby incorporated by reference in this Item 4. The Reporting Persons believe the securities of the Issuer represent an attractive investment opportunity. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending upon various factors, including, without limitation, the Issuer's financial position and strategic direction, overall market conditions, general economic and industry conditions, other investment opportunities available to the Reporting Persons, the liquidity requirements of the Reporting Persons, price levels of the Ordinary Shares and the ADSs, and any contractual provisions to which the Reporting Persons may then be subject, the Reporting Persons in the future may take actions with respect to their investment position in the Issuer as they deem appropriate, including, without limitation, purchasing additional Ordinary Shares or ADSs, other securities of the Issuer or other instruments that are based upon or relate to the value of any of the foregoing; selling, exchanging, converting, pledging or financing some or all of the securities reported herein, other securities of the Issuer or other instruments that are based upon or relate to the value of any of the foregoing; engaging in hedging or similar transactions with respect to Ordinary Shares or ADSs, other securities of the Issuer or other instruments that are based upon or relate to the value of any of the foregoing; and taking any other action to maximize the value of the Reporting Persons' investment position in the Issuer. Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, (i) review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto and (ii) consider or propose one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D.
    Item 5.Interest in Securities of the Issuer
    (a)
    The information set forth in Rows 7 through 13 of the cover page hereto for each Reporting Person is incorporated herein by reference for each such Reporting Person. The percentage amount set forth in Row 13 for all cover pages filed herewith is calculated based upon the 154,731,309 Ordinary Shares outstanding as of June 10, 2026, as reported by the Issuer in its Form 8-K filed with the Securities and Exchange Commission on June 12, 2026. The Ordinary Shares, represented by ADSs, reported hereby as beneficially owned by the Reporting Persons are held directly by the following investment partnerships, of which the Investment Manager is the investment manager: (i) Farallon Capital Partners, L.P., a California limited partnership ("FCP"); (ii) Farallon Capital Institutional Partners, L.P., a California limited partnership ("FCIP"); (iii) Farallon Capital Institutional Partners II, L.P., a California limited partnership ("FCIP II"); (iv) Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership ("FCIP III"); (v) Four Crossings Institutional Partners V, L.P., a Delaware limited partnership ("FCIP V"); (vi) Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership ("FCOI II"); (vii) Farallon Capital (AM) Investors, L.P., a Delaware limited partnership ("FCAMI"); (viii) Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership ("F5MI"); and (ix) Farallon Healthcare Partners Master, L.P., a Cayman Islands exempted limited partnership ("FHPM"). FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, FCAMI, F5MI and FHPM are together referred to herein as the "Farallon Funds."
    (b)
    The information set forth in Rows 7 through 13 of the cover page hereto for each Reporting Person is incorporated herein by reference for each such Reporting Person.
    (c)
    The dates, number of ADSs involved and the price per ADS (excluding commissions) for all transactions in the ADSs by the Farallon Funds in the past sixty days are set forth in Exhibit 99.2 attached hereto and such information is incorporated herein by reference. All of such transactions were open-market transactions.
    (d)
    No person (other than the Reporting Persons, the Farallon Funds, and the general partner of each Farallon Fund) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The disclosure set forth in Items 4 and 5 above is hereby incorporated by reference in this Item 6. Except as described above, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between such persons and any other person with respect to any securities of the Issuer, including but not limited to the transfer or voting of any securities of the Issuer, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.
    Item 7.Material to be Filed as Exhibits.
     
    There is filed herewith as Exhibit 99.1 a written agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. There is filed herewith as Exhibit 99.2 the sixty-day trading history referenced in Item 5(c).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FARALLON CAPITAL MANAGEMENT, L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member
    Date:06/24/2026
     
    Dapice Joshua J.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Dreyfuss, Philip D.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Dunn Hannah E.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn
    Date:06/24/2026
     
    Gehani, Varun N.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Giauque, Nicolas
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Husen, Avner A.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Kim, David T.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Linn, Michael G.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Luo Patrick (Cheng)
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Roberts, Jr., Thomas G.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Saito Edric C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Short Daniel S.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Spokes, Andrew J. M.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Warren, John R.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
     
    Wehrly, Mark C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:06/24/2026
    Get the next $CNTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNTA

    DatePrice TargetRatingAnalyst
    4/13/2026$38.00Buy → Hold
    Truist
    2/24/2026$40.00Outperform
    Wolfe Research
    12/10/2025$62.00Outperform
    Oppenheimer
    10/28/2025$35.00Overweight
    Stephens
    9/3/2025$31.00Overweight
    Wells Fargo
    8/29/2025$40.00Outperform
    Oppenheimer
    7/21/2025$30.00Buy
    Truist
    5/28/2025$35.00Buy
    Needham
    More analyst ratings

    $CNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Centessa Pharmaceuticals downgraded by Truist with a new price target

    Truist downgraded Centessa Pharmaceuticals from Buy to Hold and set a new price target of $38.00

    4/13/26 8:43:07 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Centessa Pharmaceuticals with a new price target

    Wolfe Research initiated coverage of Centessa Pharmaceuticals with a rating of Outperform and set a new price target of $40.00

    2/24/26 7:47:48 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Centessa Pharmaceuticals with a new price target

    Oppenheimer resumed coverage of Centessa Pharmaceuticals with a rating of Outperform and set a new price target of $62.00

    12/10/25 8:21:56 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by Centessa Pharmaceuticals plc

    SCHEDULE 13D - Centessa Pharmaceuticals plc (0001847903) (Subject)

    6/24/26 6:32:05 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Centessa Pharmaceuticals plc

    S-8 POS - Centessa Pharmaceuticals plc (0001847903) (Filer)

    6/24/26 4:07:50 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Centessa Pharmaceuticals plc

    S-8 POS - Centessa Pharmaceuticals plc (0001847903) (Filer)

    6/24/26 4:06:54 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goyal Arjun bought $5,865,242 worth of Ordinary Shares (462,585 units at $12.68) (SEC Form 4)

    4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

    5/19/25 5:49:01 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Medicxi Ventures Management (Jersey) Ltd sold 19,963,157 units of Ordinary Shares (SEC Form 4) to cover taxes

    4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

    6/24/26 4:26:57 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Index Ventures Life Vi (Jersey) L.P. sold 9,961,789 units of Ordinary Shares (SEC Form 4) (withholding obligation)

    4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

    6/24/26 4:23:35 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief People Officer Anderson Karen M. returned 62,085 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes

    4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

    6/24/26 4:16:46 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales

    BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly and Company ("Lilly"), through a wholly owned subsidiary, today announced that the High Court of Justice of England and Wales has approved the proposal for Lilly to acquire Centessa for $38.00 in cash per share plus one non-transferable contingent value right ("CVR") that entitles the holder to receive up to an aggregate of $9.00 subject to th

    6/22/26 4:05:00 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

    Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumorsPlayed a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster statusLed clinical development as CMO of NBE Therapeutics which was acquired by Boehringer Ingelheim for $1.4 billion, and most recently CMO of radiotherapy company Full-Life TechnologiesTimely key hire with Dr. Heeger's operational rigor and clinical expertise expected to elevate development of Actimab-A,

    6/1/26 8:00:00 AM ET
    $ATNM
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

    Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disordersAcquisition expands Lilly's neuroscience portfolio and capabilities into sleep medicine INDIANAPOLIS and BOSTON and LONDON, March 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, today announced a definitive agreement for Lilly to acquire Centessa.Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists des

    3/31/26 6:45:00 AM ET
    $CNTA
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Leadership Updates

    Live Leadership Updates

    View All

    Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

    BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company, today announced that its Board of Directors has appointed Mario Alberto Accardi PhD, President and founder of Centessa's Orexin Program, as Chief Executive Officer (CEO) and member of the Board, effective January 1, 2026. Dr. Accardi will succeed Saurabh Saha MD PhD, who will step down from his position as CEO and a member of the Board, effective January 1, 2026. Dr. Saha will be appointed advisor to the CEO. "This leadership transition underscores Centessa's strategic evolution from an R&D driven start-up with a diversified early-stage pipeline to an o

    12/11/25 7:00:00 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

    BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.  "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD

    1/8/25 7:05:00 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

    BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen

    6/10/24 7:00:00 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Financials

    Live finance-specific insights

    View All

    Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

    ORX750: Demonstrated potential best-in-class profile for treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) in initial cohorts of ongoing Phase 2a study; Data mark first robust demonstration of oral OX2R agonist addressing wakefulness needs of patients across all three indications; Expect to initiate registrational program in Q1 2026ORX142: Phase 1 data support highly differentiated profile; Expect to initiate patient studies in Q1 2026 ORX489: Advancing in IND-enabling studies; Expect to initiate clinical studies in Q1 2026 BOSTON and LONDON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmace

    11/5/25 7:00:00 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

    Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with data in acutely sleep-deprived healthy volunteers expected this year ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cent

    8/12/25 7:00:26 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

    Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders with clinical data in acutely sleep-deprived healthy volunteers planned for this yearORX489 advancing in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, May 14, 20

    5/14/25 7:00:53 AM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

    SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

    11/14/24 5:43:48 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

    SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

    11/14/24 4:20:32 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc (Amendment)

    SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

    2/14/24 5:37:34 PM ET
    $CNTA
    Biotechnology: Pharmaceutical Preparations
    Health Care